上海建发致新医疗科技集团股份有限公司 会计师事务所选聘制度 上海建发致新医疗科技集团股份有限公司 会计师事务所选聘制度 上海建发致新医疗科技集团股份有限公司 会计师事务所选聘制度 上海建发致新医疗科技集团股份有限公司 会计师事务所选聘制度 上海 二〇二五年十月 第一章 总则 第一条 为规范上海建发致新医疗科技集团股份有限公司（以下简称"公司"） 选聘（含续聘、改聘，下同）会计师事务所的行为，切实维护股东利益，提高审 计工作和财务信息质量，根据《中华人民共和国公司法》《国有企业、上市公司 选聘会计师事务所管理办法》《深圳证券交易所创业板股票上市规则》《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、 法规、规范性文件及《公司章程》的规定，结合公司实际情况，制定本制度。 第二条 本制度所称选聘会计师事务所，是指公司根据相关法律法规要求， 聘任会计师事务所对财务会计报告发表审计意见、出具审计报告的行为。 本制度的选聘程序不包含为公司提供专项审计服务及为公司控股子公司提 供年度审计服务的会计师事务所的选聘，若子公司确需自行选聘会计师事务所的， 需根据公司相关制度的要求履行相应审批程序 ...

建发致新公告，第三季度营收为50.32亿元，同比增长6.48%；净利润为9279.77万元，同比增长 49.14%。前三季度营收为148.61亿元，同比增长10.18%；净利润为2.3亿元，同比增长45.01%。 ...

Financial Performance - The company's operating revenue for Q3 2025 reached ¥5,031,850,801.87, representing a year-on-year increase of 6.48%[5] - Net profit attributable to shareholders was ¥92,797,723.25, up 49.14% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥90,104,355.70, reflecting a 43.01% increase year-on-year[5] - Basic and diluted earnings per share both stood at ¥0.26, marking a 49.14% increase from the previous year[5] - Total operating revenue for the current period reached ¥14,860,753,939.01, an increase of 10.2% compared to ¥13,487,182,811.91 in the previous period[20] - Net profit for the current period was ¥284,049,040.09, representing a 43.3% increase from ¥198,181,282.78 in the previous period[22] - The net profit attributable to shareholders of the parent company was ¥229,833,549.09, compared to ¥158,499,162.85, marking a growth of 45.0%[22] - Basic and diluted earnings per share for the current period were both ¥0.64, up from ¥0.44 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥14,686,136,571.84, a 12.00% increase from the end of the previous year[5] - Total liabilities increased to ¥12,266,187,059.91 from ¥11,335,476,422.64, reflecting a growth of 8.2%[18] - Shareholders' equity attributable to the parent company reached ¥2,077,221,495.65, up 40.24% from the previous year-end[5] - Total equity attributable to shareholders of the parent company rose to ¥2,077,221,495.65, compared to ¥1,481,229,497.57, an increase of 40.2%[18] - The company has a total of 14.18 billion in current assets, up from 12.60 billion, reflecting a growth of approximately 12.6%[17] - Non-current assets totaled CNY 510.35 million, slightly down from CNY 516.49 million, indicating a decrease of about 1.5%[17] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥50,576,688.13, showing a significant increase of 104.63% compared to the same period last year[5] - Operating cash inflow for the current period reached ¥17,599,539,011.49, an increase of 6.06% from ¥15,650,057,820.67 in the previous period[25] - Net cash flow from operating activities was ¥50,576,688.13, a significant recovery from a negative cash flow of ¥-1,092,588,441.89 in the previous period[25] - Cash inflow from financing activities amounted to ¥4,133,187,948.57, an increase of 6.73% from ¥3,873,360,806.34 in the previous period[27] - The ending balance of cash and cash equivalents increased to ¥1,787,466,702.66, compared to ¥903,432,646.05 in the previous period[27] - Cash received from other financing activities was ¥49,992,256.33, with no previous amount reported[27] Shareholder Information - The company reported a total of 37,987 common shareholders at the end of the reporting period[10] - The largest shareholder, Xiamen Jianfa Medical, holds a 43.37% stake, while the second-largest shareholder, Pingxiang Changheyuan Investment Management, holds 26.80%[12] Initial Public Offering - The company completed its initial public offering during the reporting period, which contributed to the increase in shareholders' equity[9] - The company successfully completed its initial public offering (IPO) of 63,193,277 shares on September 25, 2025, under the stock code "301584" on the Shenzhen Stock Exchange[14] Operational Insights - The increase in net profit is attributed to the growth in the company's SPD management services business[9] - The company has plans for market expansion and new product development as part of its growth strategy moving forward[14] - The company reported a significant increase in tax payable, which rose to ¥86,554,671.54 from ¥52,066,299.53, a growth of 66.2%[18] - The company has ongoing research and development expenses of ¥18,081,750.52, slightly up from ¥17,235,616.66, indicating continued investment in innovation[21] Inventory and Receivables - Accounts receivable increased significantly to CNY 8.05 billion from CNY 6.47 billion, representing a growth of approximately 24.3%[17] - Inventory decreased to CNY 3.29 billion from CNY 3.48 billion, showing a decline of about 4.4%[17] - Short-term borrowings slightly decreased to CNY 3.77 billion from CNY 3.85 billion, a reduction of approximately 2.9%[17] Financial Reporting - Cash outflow from investment activities totaled ¥53,310,612.12, compared to ¥51,417,469.32 in the previous period, resulting in a net cash outflow of ¥53,278,391.12[25] - The company has not audited its third-quarter financial report[28]

证券代码：301584 证券简称：建发致新 公告编号：2025-010 上海建发致新医疗科技集团股份有限公司 关于变更公司注册资本、公司类型、修订《公司章程》 及修订和新增公司部分治理制度的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 上海建发致新医疗科技集团股份有限公司（以下简称"公司"）于2025年10月 24日召开第三届董事会第十次会议，审议通过了《关于变更公司注册资本、公司类 型及修订<公司章程>并办理工商变更登记的议案》《关于制定、修订公司部分制度 的议案》，现将相关内容公告如下： 一、变更公司注册资本、公司类型的相关情况 根据中国证券监督管理委员会《关于同意上海建发致新医疗科技集团股份有限 公司首次公开发行股票注册的批复》（证监许可[2025]1337号）并经深圳证券交易 所同意，公司向社会公开发行人民币普通股（A股）股票63,193,277股。 本次发行完成后，公司注册资本由人民币358,095,232元变更为421,288,509元， 上述事项已于2025年9月22日由容诚会计师事务所（特殊普通合伙）出具《验资报 告》（容诚验字[202 ...

证券代码：301584 证券简称：建发致新 公告编号：2025-007 上海建发致新医疗科技集团股份有限公司 关于调整募投项目拟投入募集资金金额的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 上海建发致新医疗科技集团股份有限公司（以下简称"公司"）于2025年10月 24日召开第三届董事会第十次会议及第三届监事会第九次会议，审议通过了《关于 调整募投项目拟投入募集资金金额的议案》，同意公司根据实际募集资金净额对募 投项目拟投入募集资金金额进行调整。公司保荐机构中信证券股份有限公司（以下 简称"中信证券"）对该事项发表了核查意见。现将具体情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意上海建发致新医疗科技集团股 份有限公司首次公开发行股票注册的批复》（证监许可〔2025〕1337号）并经深圳 证券交易所同意，公司首次公开发行人民币普通股（A股）股票 63,193,277股，发 行价格为7.05元/股（人民币，下同），募集资金总额为44,551.26万元，扣除发行 费用8,217.81万元（不含税）后，实际募集资金净额为36 ...

证券代码：301584 证券简称：建发致新 公告编号：2025-008 上海建发致新医疗科技集团股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、现金管理产品种类：安全性高、流动性好、满足保本要求的低风险产品， 包括但不限于定期存款、通知存款、大额存单、结构性存款、证券公司保本型收 益凭证及国债逆回购等。 二、募集资金暂时闲置原因 由于公司募集资金投资的部分项目建设需要一定周期，根据募集资金投资项目 建设进度，现阶段募集资金在短期内出现闲置的情况。公司及子公司为提高资金的 使用效率，在确保不影响募集资金投资计划正常进行，并有效控制风险的前提下进 行闲置募集资金现金管理，不存在变相改变募集资金用途的行为，不会影响募集资 金投资项目的正常进行。 三、闲置募集资金进行现金管理的基本情况 （一）现金管理的目的 2、现金管理额度及期限：不超过人民币1.8亿元（含本数），该额度自公司 董事会审议通过之日起12个月内可循环滚动使用。 3、已履行的审议程序：本事项已经公司第三届董事会第十次会议、第三届 ...

证券代码：301584 证券简称：建发致新 公告编号：2025-011 上海建发致新医疗科技集团股份有限公司 关于2025年前三季度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2、资产减值损失（下表中损失以"-"列示） 上海建发致新医疗科技集团股份有限公司（以下简称 "公司 "）根据《深 圳证券交易所创业板股票上市规则》以及公司会计政策等有关规定，本着谨慎性 原则，公司持续对合并范围内截至2025年9月30日的相关资产进行清查和减值测试 并及时计提资产减值准备。公司计提资产减值准备事项是按照相关企业会计准则 及公司会计政策的相关规定执行，无需公司董事会或股东大会审议。现将相关情 况公告如下： 一、计提资产减值准备情况概述 （一）计提资产减值准备的原因 为真实客观反映公司财务状况及经营成果，基于谨慎性原则，根据《企业会 计准则第8号—资产减值》及公司会计政策等相关规定，公司持续对合并报表范围 内可能存在减值的各项资产进行充分评估和分析，并对存在一定减值迹象的资产 计提相关减值准备。 （二）计提资产减值准备的资产范围和总金额 公司计提资 ...

证券代码：301584 证券简称：建发致新 公告编号：2025-009 上海建发致新医疗科技集团股份有限公司 关于增加2025年度向银行申请综合授信额度的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2025年10月24日，上海建发致新医疗科技集团股份有限公司（以下简称"公司" ）召开第三届董事会第十次会议及第三届监事会第九次会议，审议通过了《关于增 加2025年度向银行申请综合授信额度的议案》，该议案尚需提交公司股东大会审议。 现将相关内容公告如下： 1 在上述授信额度内办理具体授信业务时，授权对应主体的法定代表人根据公司有关 规定签署相关法律文件。上述授权有效期至公司2025年年度股东大会召开之日止。 一、已审批的综合授信额度的情况 公司于2025年3月28日召开第三届董事会第八次会议及第三届监事会第七次会 议，并于2025年4月18日召开2024年年度股东大会审议通过了《关于公司2025年度 向银行申请综合授信的议案》，同意公司及控股子公司2025年度向银行申请综合授 信总额度不超过110亿元（人民币，下同）。截止2025年9月30日，公司及控股 ...

- The report tracks the recent IPO market performance, focusing on the net gains from new stock listings across the Sci-Tech Innovation Board, ChiNext, and Main Board, assuming all stocks are successfully subscribed and sold at the market average price on the first trading day, excluding lock-up restrictions[1][11][39] - The cumulative IPO net gains for A-class accounts with a scale of 2 billion reached 2.44%, while B-class accounts of the same scale achieved 2.19% as of October 24, 2025[11][39] - For larger accounts with a scale of 10 billion, the IPO net gains were significantly lower, with A-class accounts at 0.77% and B-class accounts at 0.70%[11][39] - The average first-day price increase for Sci-Tech Innovation Board stocks was 218.45%, while ChiNext stocks saw an average increase of 244.28%[1][16] - The report provides detailed calculations for theoretical IPO gains, using formulas such as: $ Full subscription quantity = Maximum subscription limit × Average offline subscription rate $ $ Full subscription gains = (First-day average price - IPO price) × Full subscription quantity $[35][39] - The highest full subscription gains among recent IPOs were achieved by United Power, Jindal Zhixin, and C Marco, with gains of 50.81, 12.58, and 11.03 million yuan respectively[35][38] - The report also includes monthly tracking of IPO gains for A-class accounts across different scales, showing a cumulative gain rate of 6.17% for 2 billion accounts since 2024, and 2.44% for 2025 alone[39][41] - Similar tracking for B-class accounts reveals a cumulative gain rate of 5.11% for 2 billion accounts since 2024, and 2.19% for 2025 alone[47][45] - The report highlights the IPO subscription process, including strategic placement, offline inquiry, and online pricing methods, with detailed statistics on subscription rates, oversubscription multiples, and effective subscription ratios for recent IPOs like Xi'an Yicai and Bibet[24][25]

证券日报网讯建发致新（301584）10月27日在互动平台回答投资者提问时表示，公司目前没有脑机接口 类产品的销售，没有相关的技术研发和储备。 ...